News
Heavy and painful periods linked to lower grades and attendance, study reveals

New research has found that heavy periods and menstrual pain in teenage girls are linked to lower grades and increased school absences.
The study, described as the most robust to date on this issue, examined data from 2,698 girls aged 13 to 16 in the Children of the 90s study, linking health records to school attendance and GCSE results from the Department for Education.
Led by the University of Bristol with the University of Exeter and funded by Wellcome, the study found 36 per cent of girls experienced heavy or prolonged bleeding.
This group missed an extra 1.7 school days a year and had a 27 per cent lower chance of achieving five GCSE passes.
Meanwhile, 56 per cent reported menstrual pain, which was linked to missing 1.2 more school days a year and a 16 per cent lower chance of achieving five passes.
Girls reporting both heavy bleeding and pain were more likely to be persistently absent from school.
Researchers said absence alone did not fully explain the effect on grades, with existing evidence showing symptoms also affect concentration.
Gemma Sawyer, PhD student at the University of Bristol who conducted the research, said: “Our large-scale study provides the most convincing evidence to date that menstrual symptoms are associated with lower attendance and attainment.
“This work supports what young people have reported struggling with in previous studies.
The link between menstrual symptoms and education remained even after taking into account factors such as maternal education, financial difficulties, ethnicity and age at starting menstruation.
Teenage girls in a focus group described challenges such as difficulty concentrating during periods, limited toilet access, embarrassment and stigma and lack of period products.
Gemma Sharp, professor of epidemiology at the University of Exeter who supervised the research, said: “We know from previous research that heavy and painful periods can impact attendance and concentration, and this study tells us that there’s also a link with attainment.
“It’s clear that people are capable of functioning at a high level regardless of their cycle, but we need a society that’s better set up to support them, particularly if they are experiencing heavy bleeding and pain.”
A team of researchers, led by Professor Sharp, has secured US$4.5m in funding from Wellcome Leap, obtained with support from regional university alliance GW4.
The funding will support new research to tackle the widespread and often overlooked issue of heavy menstrual bleeding in women.
Professor Sharp will use data from Bristol’s Children of the 90s and Born in Bradford cohorts to investigate biological factors underlying heavy bleeding.
This research forms part of the US$50m Missed Vital Sign programme – a global initiative aimed at earlier identification of heavy menstrual bleeding and the development of faster, more personalised care for women worldwide.
Hormonal health
Study links small bowel microbiome differences to women’s health
Menopause
Cancer drug could tackle osteoporosis menopause weight gain

An experimental cancer drug reduced bone loss and body fat in mice modelling post-menopausal changes, early research suggests.
The compound, CADD522, appeared to strengthen bones and help the animals stay leaner after surgery designed to mimic hormonal changes seen after menopause.
The treatment remains at an early experimental stage and has so far only been tested in animals.
The study, led by the University of East Anglia, investigated CADD522, which was originally developed to block a protein involved in the growth and spread of several cancers.
Mice treated with the compound for eight weeks showed significant improvements in bone health. Scans found increased bone volume and better preservation of the honeycomb-like structures inside bones that are crucial for strength and resilience.
Blood tests suggested the treatment stimulated new bone growth without interfering with the body’s normal process of breaking down and rebuilding bone.
Dr Darrell Green, lead researcher from UEA’s Norwich Medical School, said: “Osteoporosis affects around one in three women over the age of 50, leaving sufferers vulnerable to painful fractures that can seriously impact quality of life.
“Current treatments exist, but many are plagued by side effects, safety concerns or inconvenient dosing schedules that make long-term use difficult.”
The researchers also found that mice receiving CADD522 weighed less than untreated mice despite eating the same amount of food.
They had less body fat and fewer fat deposits in their bone marrow, a process commonly seen after menopause and linked to declining bone health.
The team also examined brain tissue and found that the drug appeared to reverse several menopause-related changes in fatty acids.
Levels of omega-3 fats including DHA remained largely intact, while several other lipid abnormalities shifted back towards healthier patterns.
Green said: “We didn’t directly test for memory or thinking ability, but our work raises questions about whether this drug could one day help address wider menopause-related health problems.”
Safety experiments in mice, rats and dogs found that CADD522 could be taken orally and was well tolerated.
The compound also appeared to be metabolised more slowly in human tissue than in rodents, potentially improving its performance in people.
“This is still in the early stages and has so far only been tested in animals but we hope that the benefits will translate to humans to ultimately reduce fracture rates,” added Green.
The research was led by UEA in collaboration with the University of Maryland, the Scintillon Research Institute in San Diego and the University of Stirling.
Safety testing was funded by The Sir William Coxen Trust as part of the development of CADD522 as a childhood cancer treatment.
Fertility
Weight loss surgery improves menstrual health and PMOS symptoms, study finds

Weight loss surgery was linked to more regular periods and fewer polyendocrine metabolic ovarian syndrome (PMOS) symptoms in women aged 18 to 45 living with obesity in a recent study.
The researchers recommend that women undergoing the procedure have access to preconception care and reproductive counselling to support their reproductive health.
Researchers at the University of Surrey analysed data over 24 months from 84 women who underwent bariatric surgery and 18 women living with obesity who did not have surgery.
Of those who underwent surgery, 49 had gastric bypass procedures and 35 had gastric sleeve surgery.
Women who underwent metabolic bariatric surgery lost more than 30kg on average at 12 and 24 months after the procedure.
Among women with polycystic ovaries, the condition persisted in only 10 per cent after 24 months.
Women also reported a resolution of clinical hirsutism, or excess body hair, by 12 months.
Women who had previously experienced irregular periods reported more regular menstrual cycles after surgery.
Professor Martin Whyte, co-author of the study and professor of metabolic medicine at the University of Surrey, said: “A large proportion of those undergoing bariatric surgery are women of reproductive age, who may be planning a pregnancy in the coming years.
“So much remains unknown about the impact of this type of surgery on women who are planning to have children.
“This raises the question of when the ideal time after surgery is to conceive.”
Women have a higher prevalence of obesity than men, with 57 per cent of women in the UK classified as overweight and 27 per cent living with obesity, which can affect fertility and the health of an unborn baby.
The researchers said 17 women had healthy pregnancies following surgery.
Although this was not specifically examined in the study, no difference in birth weight was observed between babies conceived within or after the first year.
Dr Kathryn Hart, co-author of the study and associate professor in nutrition and dietetics at the University of Surrey, said: “What we have found is that bariatric surgery positively affects the reproductive health of women living with obesity and can improve the likelihood of them having a healthy pregnancy after surgery.
“Dysregulated hormone levels, irregular periods and conditions such as polycystic ovaries are affected by obesity.
“By reducing this, what we have seen is that it can lead to improvements without the need for medication.
“We would suggest that clinicians consider medical intervention for obesity to treat irregularities in the menstrual cycle and issues with fertility.”
Diagnosis2 weeks agoMajor UK study could be a ‘game-changer’ for heavy periods and endometriosis
Entrepreneur7 days agoKOVE Medical raises €1.7 million to improve safety of foetal surgery
Fertility2 weeks agoOne week left to apply: W Accelerate with Merck KGaA and M Ventures
Mental health1 week agoUK study aims to transform maternity care for high-risk pregnancies
Menopause2 weeks agoQuarter of women miss work due to menstual symptoms, survey finds
Mental health2 weeks agoPMDD after SSRIs or hormones: Why the brain may be the missing treatment target
Diagnosis2 weeks agoArk Surgical secures further institutional backing to accelerate US expansion
Menopause5 days agoMenopause hormone treatment may ease brain fog, study suggests













